Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149.
Maria Creselda deLeon
No relevant relationships to disclose
Alesha Arnold
No relevant relationships to disclose
Emma Caroline Rossi
No relevant relationships to disclose
Jamie Case
No relevant relationships to disclose
Cynthia Johnson
No relevant relationships to disclose
Yan Zeng
No relevant relationships to disclose
Daniela Matei
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim